

Appendix: Tables

1.	Sales January to June 2026 and 2025	2
2.	Quarterly sales and constant exchange rate sales growth by Division in 2026 and 2025	3
3.	Product sales Pharmaceuticals Division and constant exchange rate growth YTD June 2026 vs. YTD June 2025	4
4.	Top 20 Pharmaceuticals Division quarterly product sales and quarterly constant exchange rate sales growth	6
5.	Top 20 Pharmaceuticals Division quarterly product sales and quarterly constant exchange rate sales growth United States	7
6.	Top 20 Pharmaceuticals Division quarterly product sales and quarterly constant exchange rate sales growth Europe	8
7.	Top 20 Pharmaceuticals Division quarterly product sales and quarterly constant exchange rate sales growth Japan	9
8.	Top 20 Pharmaceuticals Division quarterly product sales and quarterly constant exchange rate sales growth International	10
9.	Roche Group consolidated income statement for the six months ended 30 June 2026	11
10.	Roche Group core results reconciliation – Half Year 2026	12
11.	Divisional core results reconciliation – Half Year 2026	13
12.	Roche Group consolidated balance sheet.....	14
13.	Roche Group consolidated statement of cash flows	15

1. Sales January to June 2026 and 2025

CHF millions	Six months ended 30 June		% change	
	2026	2025	At CER	In CHF
Pharmaceuticals Division	23,629	23,985	6	-1
United States	12,229	12,670	6	-3
Europe	4,520	4,566	1	-1
Japan	1,360	1,425	11	-5
International	5,520	5,324	10	4
Diagnostics Division	6,735	6,959	3	-3
Roche Group	30,364	30,944	6	-2

International: Asia-Pacific, CEETRIS (Central Eastern Europe, Türkiye, Russia and Indian Sub-Continent), Latin America, Middle East, Africa, Canada, others

2. Quarterly sales and constant exchange rate sales growth by Division in 2026 and 2025

CHF millions	Q2 2025	% change vs. Q2 2024	Q3 2025	% change vs. Q3 2024	Q4 2025	% change vs. Q4 2024	Q1 2026	% change vs. Q1 2025	Q2 2026	% change vs. Q2 2025
Pharmaceuticals Division	12,036	11	11,570	7	12,114	9	11,469	7	12,160	6
United States	6,446	13	6,128	5	6,557	9	5,693	5	6,536	7
Europe	2,246	5	2,252	5	2,346	7	2,234	-1	2,286	3
Japan	754	7	714	6	743	4	649	14	711	9
International	2,590	11	2,476	11	2,468	16	2,893	16	2,627	4
Diagnostics Division	3,468	0	3,348	2	3,540	6	3,253	3	3,482	4
Roche Group	15,504	8	14,918	6	15,654	8	14,722	6	15,642	5

International: Asia-Pacific, CEETRIS (Central Eastern Europe, Türkiye, Russia and Indian Sub-Continent), Latin America, Middle East, Africa, Canada, others

3. Product sales Pharmaceuticals Division and constant exchange rate growth YTD June 2026 vs. YTD June 2025

CHF millions	Total		United States		Europe		Japan		International	
	CHF m	%	CHF m	%	CHF m	%	CHF m	%	CHF m	%
Ocrevus	3,470	7	2,300	2	758	10	-	-	412	30
Hemlibra	2,492	11	1,313	9	502	4	171	9	506	26
Vabysmo	2,059	8	1,333	1	386	5	75	26	265	65
Tecentriq	1,704	6	815	9	410	-3	146	-2	333	17
Xolair	1,673	27	1,673	27	-	-	-	-	-	-
Perjeta	1,389	-7	551	-11	238	-14	24	-23	576	0
Phesgo	1,318	18	318	0	425	9	88	15	487	47
Actemra/RoActemra	1,074	-9	515	-9	238	-21	140	8	181	-3
Evrysdi	968	17	323	15	335	17	39	-1	271	25
Kadcyla	916	-6	310	-14	248	-4	39	2	319	3
Polivy	808	20	381	28	128	-18	98	16	201	47
Alecensa	795	6	261	4	126	-4	93	8	315	13
MabThera/Rituxan	609	5	402	14	62	-9	6	-11	139	-10
Activase/TNKase	555	11	531	11	-	-	-	-	24	12
Gazyva	489	7	240	4	117	-1	17	14	115	21
Herceptin	462	-12	94	-14	136	-7	2	-36	230	-14
Avastin	414	-15	125	-12	35	37	36	-44	218	-13
Pulmozyme	204	-8	145	-5	29	-11	-	26	30	-18
Columvi	196	70	91	28	53	116	-	-	52	173
Enspryng	195	22	50	20	23	20	79	18	43	37
Elevidys	180	62	-	-	2	-	22	-	156	39
Itovebi	104	212	81	164	7	*	-	-	16	*
Lunsumio	100	130	65	136	9	-17	21	348	5	500

Xofluza	74	-58	22	37	2	24	-	-	50	-69
Rozlytrek	66	-10	16	-33	12	10	2	-18	36	1
PiaSky	30	62	-	-	7	140	22	47	1	-7
Cotellic	23	2	11	7	5	-9	-	-	7	2
Luxturna	22	-32	22	-32	-	-	-	-	-	-
Susvimo	9	109	9	109	-	-	-	-	-	-
Pharma other	1,231	-8	232	-22	227	0	240	26	532	-15
Pharma total sales	23,629	6	12,229	6	4,520	1	1,360	11	5,520	10

International: Asia-Pacific, CEETRIS (Central Eastern Europe, Türkiye, Russia and Indian Sub-Continent), Latin America, Middle East, Africa, Canada, others

* Over 500%

4. Top 20 Pharmaceuticals Division quarterly product sales and quarterly constant exchange rate sales growth

CHF millions	Q2 2025	% change vs. Q2 2024	Q3 2025	% change vs. Q3 2024	Q4 2025	% change vs. Q4 2024	Q1 2026	% change vs. Q1 2025	Q2 2026	% change vs. Q2 2025
Ocrevus	1,728	10	1,684	6	1,820	16	1,692	6	1,778	7
Hemlibra	1,256	22	1,105	4	1,228	8	1,190	13	1,302	9
Vabysmo	1,049	19	996	4	1,039	7	1,024	13	1,035	3
Tecentriq	863	-1	883	4	950	8	811	4	893	9
Xolair	800	41	781	34	849	26	708	26	965	28
Perjeta	773	-14	703	-14	652	-13	672	-11	717	-3
Phesgo	604	57	630	51	614	34	686	27	632	9
Actemra/RoActemra	660	8	614	-2	577	-10	534	-4	540	-14
Evrysdi	449	-1	424	10	464	26	464	19	504	16
Kadcyla	531	12	494	7	494	6	439	-4	477	-7
Polivy	372	51	371	30	369	31	407	26	401	14
Alecensa	405	6	388	8	372	1	401	12	394	1
MabThera/Rituxan	332	1	303	3	318	-3	292	10	317	0
Activase/TNKase	253	-7	283	1	274	-2	255	-2	300	24
Gazyva	241	12	238	13	258	15	247	10	242	4
Herceptin	268	-23	257	-15	211	-29	234	-12	228	-12
Avastin	248	-19	241	-11	210	-21	224	-9	190	-20
Pulmozyme	116	13	122	26	118	1	89	-18	115	3
Columvi	63	58	79	71	86	64	95	77	101	64
Enspryng	94	27	92	25	95	17	96	31	99	15

5. Top 20 Pharmaceuticals Division quarterly product sales and quarterly constant exchange rate sales growth United States

CHF millions	Q2 2025	% change vs. Q2 2024	Q3 2025	% change vs. Q3 2024	Q4 2025	% change vs. Q4 2024	Q1 2026	% change vs. Q1 2025	Q2 2026	% change vs. Q2 2025
Ocrevus	1,215	8	1,151	1	1,261	17	1,117	3	1,183	2
Hemlibra	714	21	617	-1	724	6	613	15	700	4
Vabysmo	732	10	689	-4	718	-1	652	4	681	-2
Tecentriq	408	-4	403	2	418	4	378	6	437	12
Xolair	800	41	781	34	849	26	708	26	965	28
Perjeta	335	4	291	-6	300	4	263	-12	288	-10
Phesgo	169	40	175	29	185	22	159	2	159	-2
Actemra/RoActemra	325	11	307	-6	280	-19	248	-3	267	-13
Evrysdi	149	10	159	18	144	0	160	15	163	15
Kadcyla	195	9	181	2	191	10	156	-11	154	-17
Polivy	171	34	170	18	191	32	171	26	210	29
Alecensa	146	19	144	15	145	4	105	-7	156	13
MabThera/Rituxan	206	2	188	5	219	5	183	16	219	13
Activase/TNKase	242	-5	270	1	259	-2	244	-2	287	24
Gazyva	122	14	123	14	143	20	115	1	125	8
Herceptin	61	-8	54	-6	50	-14	44	-16	50	-13
Avastin	76	-18	69	-16	74	-14	59	-15	66	-8
Pulmozyme	83	22	87	30	89	8	58	-21	87	11
Columvi	41	88	47	90	53	70	43	35	48	23
Enspryng	25	20	25	9	26	1	22	20	28	20

6. Top 20 Pharmaceuticals Division quarterly product sales and quarterly constant exchange rate sales growth Europe

CHF millions	Q2 2025	% change vs. Q2 2024	Q3 2025	% change vs. Q3 2024	Q4 2025	% change vs. Q4 2024	Q1 2026	% change vs. Q1 2025	Q2 2026	% change vs. Q2 2025
Ocrevus	362	14	354	12	391	14	363	9	395	11
Hemlibra	246	7	247	14	262	12	252	5	250	3
Vabysmo	181	25	178	9	185	13	190	0	196	10
Tecentriq	214	1	216	0	228	7	202	-6	208	-1
Xolair	-	-	-	-	-	-	-	-	-	-
Perjeta	138	-15	136	-14	134	-7	119	-15	119	-12
Phesgo	202	13	201	9	210	9	206	7	219	10
Actemra/RoActemra	156	-7	142	-1	138	-7	124	-16	114	-27
Evrysdi	147	3	158	7	166	21	159	13	176	21
Kadcyla	131	-5	130	-5	136	0	123	-6	125	-3
Polivy	66	119	68	21	62	26	63	-32	65	1
Alecensa	65	-7	64	-10	65	-3	63	-5	63	-2
MabThera/Rituxan	35	-6	34	13	36	-13	31	-8	31	-9
Activase/TNKase	-	-	-	-	-	-	-	-	-	-
Gazyva	61	4	62	1	62	5	57	-2	60	-1
Herceptin	73	-2	73	2	68	-9	69	-7	67	-6
Avastin	12	-46	28	47	16	-22	14	3	21	76
Pulmozyme	16	-16	15	-3	16	-9	15	-14	14	-7
Columvi	13	70	18	51	19	65	21	84	32	142
Enspryng	9	36	11	37	10	36	11	20	12	21

7. Top 20 Pharmaceuticals Division quarterly product sales and quarterly constant exchange rate sales growth Japan

CHF millions	Q2 2025	% change vs. Q2 2024	Q3 2025	% change vs. Q3 2024	Q4 2025	% change vs. Q4 2024	Q1 2026	% change vs. Q1 2025	Q2 2026	% change vs. Q2 2025
Ocrevus	-	-	-	-	-	-	-	-	-	-
Hemlibra	101	12	92	11	102	5	81	18	90	3
Vabysmo	38	28	35	17	41	15	37	39	38	16
Tecentriq	93	-2	88	-1	87	-6	69	0	77	-4
Xolair	-	-	-	-	-	-	-	-	-	-
Perjeta	19	-35	17	-27	15	-31	12	-19	12	-26
Phesgo	50	59	49	41	49	11	42	23	46	8
Actemra/RoActemra	81	6	78	4	80	6	66	9	74	7
Evrysdi	26	9	22	7	22	-9	18	4	21	-5
Kadcyla	24	0	23	-2	23	-7	19	6	20	-1
Polivy	55	14	54	14	54	5	46	24	52	10
Alecensa	51	-1	51	13	53	7	43	4	50	12
MabThera/Rituxan	4	-12	4	-3	3	-11	3	-6	3	-16
Activase/TNKase	-	-	-	-	-	-	-	-	-	-
Gazyva	9	3	8	22	10	37	9	28	8	0
Herceptin	2	-46	2	-30	1	-33	1	-24	1	-47
Avastin	40	-21	35	-19	34	-21	21	-29	15	-56
Pulmozyme	-	-11	-	13	1	-21	-	43	-	14
Columvi	-	-	-	-	-	-	-	-	-	-
Enspryng	41	24	42	22	44	20	35	13	44	22

8. Top 20 Pharmaceuticals Division quarterly product sales and quarterly constant exchange rate sales growth International

CHF millions	Q2 2025	% change vs. Q2 2024	Q3 2025	% change vs. Q3 2024	Q4 2025	% change vs. Q4 2024	Q1 2026	% change vs. Q1 2025	Q2 2026	% change vs. Q2 2025
Ocrevus	151	23	179	35	168	11	212	24	200	37
Hemlibra	195	60	149	9	140	18	244	14	262	39
Vabysmo	98	130	94	111	95	118	145	126	120	24
Tecentriq	148	7	176	17	217	25	162	14	171	20
Xolair	-	-	-	-	-	-	-	-	-	-
Perjeta	281	-27	259	-21	203	-30	278	-9	298	10
Phesgo	183	230	205	213	170	122	279	78	208	19
Actemra/RoActemra	98	25	87	7	79	6	96	5	85	-10
Evrysdi	127	-15	85	4	132	116	127	40	144	14
Kadcyla	181	33	160	28	144	9	141	5	178	1
Polivy	80	94	79	105	62	67	127	120	74	-7
Alecensa	143	2	129	8	109	-3	190	39	125	-13
MabThera/Rituxan	87	2	77	-5	60	-22	75	6	64	-24
Activase/TNKase	11	-37	13	18	15	-4	11	-4	13	29
Gazyva	49	18	45	24	43	8	66	45	49	-1
Herceptin	132	-34	128	-25	92	-42	120	-14	110	-14
Avastin	120	-15	109	-13	86	-26	130	-1	88	-26
Pulmozyme	17	7	20	34	12	-19	16	-12	14	-24
Columvi	9	-16	14	48	14	45	31	204	21	135
Enspryng	19	40	14	60	15	32	28	93	15	-11

International: Asia-Pacific, CEETRIS (Central Eastern Europe, Türkiye, Russia and Indian Sub-Continent), Latin America, Middle East, Africa, Canada, others

9. Roche Group consolidated income statement for the six months ended 30 June 2026

in millions of CHF	Pharma- ceuticals	Diagnostics	Corporate	Group
Sales	23,629	6,735	-	30,364
Other revenue	965	123	-	1,088
Cost of sales	(4,355)	(3,626)	-	(7,981)
Research and development	(6,336)	(901)	-	(7,237)
Selling, general and administration	(3,181)	(1,481)	(2,131)	(6,793)
Other operating income and expense	116	20	94	230
Operating profit	10,838	870	(2,037)	9,671
Financing costs				(642)
Other financial income (expense)				(56)
Profit before taxes				8,973
Income taxes				(1,648)
Net income				7,325
Attributable to				
- Roche shareholders				6,871
- Non-controlling interests				454
Earnings per share and non-voting equity security				
Basic (CHF)				8.63
Diluted (CHF)				8.52

10. Roche Group core results reconciliation – Half Year 2026

in millions of CHF

	IFRS	Global restructuring	Intangibles amortisation	Intangibles impairment	Mergers and acquisitions and alliance transactions	Legal & environmental	Pension plan settlements	Global issues	Normalisation of ECP tax benefit	Core
Sales	30,364	-	-	-	-	-	-	-	-	30,364
Other revenue	1,088	-	-	-	-	-	-	-	-	1,088
Cost of sales	(7,981)	130	178	-	-	-	-	-	-	(7,673)
Research and development	(7,237)	216	211	1,045	-	-	-	-	-	(5,765)
Selling, general and administration	(6,793)	421	2	-	-	-	-	-	-	(6,370)
Other operating income and expense	230	(2)	-	-	(18)	2	-	-	-	212
Operating profit	9,671	765	391	1,045	(18)	2	-	-	-	11,856
Financing costs	(642)	-	-	-	7	4	-	-	-	(631)
Other financial income (expense)	(56)	-	-	-	-	-	-	-	-	(56)
Profit before taxes	8,973	765	391	1,045	(11)	6	-	-	-	11,169
Income taxes	(1,648)	(155)	(75)	(96)	3	(1)	-	-	19	(1,953)
Net income	7,325	610	316	949	(8)	5	-	-	19	9,216
Attributable to										
- Roche shareholders	6,871	598	316	949	(8)	5	-	-	19	8,750
- Non-controlling interests	454	12	-	-	-	-	-	-	-	466
EPS - diluted (CHF)	8.52	0.74	0.39	1.18	(0.01)	0.01	-	-	0.02	10.85

11. Divisional core results reconciliation – Half Year 2026

in millions of CHF

	IFRS	Global restructuring	Intangibles amortisation	Intangibles impairment	Mergers and acquisitions and alliance transactions	Legal & environmental	Pension plan settlements	Core
Pharmaceuticals								
Sales	23,629	-	-	-	-	-	-	23,629
Other revenue	965	-	-	-	-	-	-	965
Cost of sales	(4,355)	14	110	-	-	-	-	(4,231)
Research and development	(6,336)	185	211	1,045	-	-	-	(4,895)
Selling, general and administration	(3,181)	150	-	-	-	-	-	(3,031)
Other operating income and expense	116	(3)	-	-	(23)	5	-	95
Operating profit	10,838	346	321	1,045	(23)	5	-	12,532
Diagnostics								
Sales	6,735	-	-	-	-	-	-	6,735
Other revenue	123	-	-	-	-	-	-	123
Cost of sales	(3,626)	116	68	-	-	-	-	(3,442)
Research and development	(901)	31	-	-	-	-	-	(870)
Selling, general and administration	(1,481)	91	2	-	-	-	-	(1,388)
Other operating income and expense	20	1	-	-	1	-	-	22
Operating profit	870	239	70	-	1	-	-	1,180
Corporate								
Selling, general and administration	(2,131)	180	-	-	-	-	-	(1,951)
Other operating income and expense	94	-	-	-	4	(3)	-	95
Operating profit	(2,037)	180	-	-	4	(3)	-	(1,856)

12. Roche Group consolidated balance sheet

in millions of CHF	30 June 2026	31 December 2025	31 December 2024
Non-current assets			
Property, plant and equipment	22,457	21,949	22,557
Right-of-use assets	952	985	1,183
Goodwill	7,769	7,492	7,876
Intangible assets	19,320	19,321	17,303
Deferred tax assets	8,721	8,411	8,569
Defined benefit plan assets	1,506	1,791	2,256
Other non-current assets	2,039	2,025	2,021
Total non-current assets	62,764	61,974	61,765
Current assets			
Inventories	8,094	7,479	7,606
Accounts receivable	12,915	11,506	11,297
Current income tax assets	428	393	415
Other current assets	4,266	3,875	3,401
Marketable securities	4,286	9,894	10,342
Cash and cash equivalents	5,448	5,582	6,975
Total current assets	35,437	38,729	40,036
Total assets	98,201	100,703	101,801
Non-current liabilities			
Long-term debt	(25,222)	(27,430)	(30,722)
Net deferred tax liabilities	(824)	(884)	(832)
Defined benefit plan liabilities	(3,904)	(3,950)	(4,381)
Provisions	(1,157)	(1,055)	(1,079)
Other non-current liabilities	(1,531)	(1,503)	(1,603)
Total non-current liabilities	(32,638)	(34,822)	(38,617)
Current liabilities			
Short-term debt	(6,583)	(4,206)	(3,932)
Current income tax liabilities	(3,231)	(2,867)	(2,923)
Provisions	(1,630)	(1,743)	(1,726)
Accounts payable	(5,542)	(5,779)	(4,894)
Other current liabilities	(11,861)	(13,406)	(13,548)
Total current liabilities	(28,847)	(28,001)	(27,023)
Total liabilities	(61,485)	(62,823)	(65,640)
Total net assets	36,716	37,880	36,161
Equity			
Capital and reserves attributable to Roche shareholders	32,693	33,802	31,767
Equity attributable to non-controlling interests	4,023	4,078	4,394
Total equity	36,716	37,880	36,161

13. Roche Group consolidated statement of cash flows

in millions of CHF	HY 2026	HY 2025
Cash flows from operating activities		
Cash generated from operations	13,739	13,791
(Increase) decrease in net working capital	(3,671)	(3,470)
Payments made for defined benefit plans	(331)	(326)
Utilisation of provisions	(529)	(658)
Other operating cash flows	0	0
Cash flows from operating activities, before income taxes paid	9,208	9,337
Income taxes paid	(1,573)	(2,237)
Total cash flows from operating activities	7,635	7,100
Cash flows from investing activities		
Purchase of property, plant and equipment	(1,570)	(1,680)
Purchase of intangible assets	(1,301)	(1,476)
Disposal of property, plant and equipment	20	73
Disposal of intangible assets	0	2
Disposal of products	5	0
Business combinations and asset acquisitions	(402)	(895)
Divestment of subsidiaries	0	6
Interest and dividends received	73	88
Sales of marketable securities	262	123
Purchases of marketable securities	(166)	(61)
Sales (purchases) of money market instruments and time accounts over three months, net	5,465	5,665
Other investing cash flows	33	(12)
Total cash flows from investing activities	2,419	1,833
Cash flows from financing activities		
Proceeds from issue of bonds and notes	0	0
Redemption and repurchase of bonds and notes	(1,715)	(2,479)
Increase (decrease) in commercial paper	1,553	3,453
Increase (decrease) in other debt	(65)	292
Hedging and collateral arrangements	(284)	(156)
Interest paid	(538)	(588)
Principal portion of lease liabilities paid	(169)	(199)
Dividends paid	(8,273)	(7,943)
Reduction of the nominal value of bearer shares paid to Roche shareholders	(107)	-
Equity-settled equity compensation plans, net of transactions in own equity	(583)	(504)
Other financing cash flows	0	1
Total cash flows from financing activities	(10,181)	(8,123)
Net effect of currency translation on cash and cash equivalents	(7)	(231)
Increase (decrease) in cash and cash equivalents	(134)	579
Cash and cash equivalents at beginning of period	5,582	6,975
Cash and cash equivalents at end of period	5,448	7,554